4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Major Depressive Disorder by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 688 ongoing clinical trials involving Major Depressive Disorder
Of the 688 trials,242 trials are in Phase II
Furthermore, 205 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Major Depressive Disorder by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Major Depressive Disorder, a Central Nervous System condition. The largest number of ongoing clinical trials for Major Depressive Disorder is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Major Depressive Disorder-related drug trials.

Johnson & Johnson: The leading ongoing Major Depressive Disorder related clinical trial sponsor

Johnson & Johnson is the top sponsor for Major Depressive Disorder-related ongoing clinical trials.

Shanghai Mental Health Center, H. Lundbeck AS, Yale University, Tehran University of Medical Sciences, and New York State Psychiatric Institute are among other notable clinical trial sponsors involved in Major Depressive Disorder. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Major Depressive Disorder

Brexpiprazole (Rexulti, Rxulti), Duloxetine hydrochloride (Cymbalta/ Xeristar /Ariclaim/Nodetrip/ Andepra), and Vortioxetine hydrobromide (Brintellix, Trintellix) are among the key marketed drugs involving Major Depressive Disorder.

Brexpiprazole (Rexulti, Rxulti) is a quinolinone derivative, acts as an anti-psychotic agent. It functions via 5-Hydroxytryptamine Receptor 1A Agonist; 5-Hydroxytryptamine Receptor 2A Antagonist; Alpha 1B Adrenergic Receptor Antagonist; Alpha 2C Adrenergic Receptor Antagonist; D2 Dopamine Receptor Agonist; D3 Dopamine Receptor Agonist mechanism of action. It is formulated as tablets, and film coated tablets for oral route of administration. Rexulti is indicated for treatment of schizophrenia, as a maintenance treatment of schizophrenia in adults and as an adjunctive treatment of major depressive disorder (MDD). Brexpiprazole was first approved in 2015 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Otsuka America Pharmaceutical Inc.

Duloxetine hydrochloride (Cymbalta / Xeristar /Ariclaim/Nodetrip/ Andepra) is a naphthalene derivative act as antidepressive agent. It functions via Sodium Dependent Noradrenaline Transporter Inhibitor, Sodium Dependent Serotonin Transporter Inhibitor mechanism of action. It is formulated as enteric-coated hard gelatin capsules for the oral route of administration. Duloxetine is used for the treatment of the major depressive disorder, generalized anxiety disorder, pain due to diabetic peripheral neuropathy, fibromyalgia in adults and pediatrics and chronic musculoskeletal pain. Duloxetine hydrochloride was first approved in 2004 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Eli Lilly and Co.